Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAP8MV)

Drug Name
Iron Drug Info
Synonyms
Eisen; Feronate; Ferretts; Ferrousal; Ferrum; Hemocyte; Hierro; LOHA; PZhO; Remko; Siderol; Yieronia; Ancor B; Armco iron; Carbonyl iron; Ferrous iron; Ferrovac E; Hoeganaes EH; Iron monocation; Iron standard for AAS; ATW 230; ATW 432; Atomel 28; Atomel 300M200; Atomel 500M; Atomel 95; Atomiron 44MR; Atomiron 5M; Atomiron AFP 25; Atomiron AFP 5; DSP 1000; DSP 128B; DSP 135; DSP 135C; DSP 138; EF 1000; EF 250; EFV 250; GS 6; HS 4849; Hoeganaes ATW 230; NC 100; PZh1M1; PZh2M; PZh2M1; PZh2M2; PZh3; PZh3M; PZh4M; Ancoren 80/150; Copy Powder CS 105-175; Diseases, iron overload; EFV 200/300; EFV 250/400; F 60 (metal); FT 3 (element); Fe-40; Fe1+; Ferro-Caps; Ferro-Time; HF 2 (element); HL (iron); HQ (metal); HS (iron); Iron (Fe); Iron(III) nitrate solution; Iron, elemental; PZh-1M3; PZh-2; SUY-B 2; Vitedyn-Slo; Diseases (animal), iron overload; Ed-In-Sol; Iron (Fe1+); Iron ion (Fe+); Iron ion(1+); Iron(1+); Iron(1+) ion; Iron, ion (Fe1+); Iron, ion (Fe1+) (8CI,9CI); 3ZhP
Indication
Disease Entry ICD 11 Status REF
Iron-deficiency anemia 3A00 Approved [1]
Therapeutic Class
Iron Supplement
Cross-matching ID
PubChem CID
23925
ChEBI ID
CHEBI:18248
CAS Number
CAS 7439-89-6
TTD Drug ID
DMAP8MV
VARIDT Drug ID
DR00317
INTEDE Drug ID
DR0882

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Transported By Natural resistance-associated macrophage protein 2 (SLC11A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Manganese DMKT129 Discovery agent N.A. Investigative [4]
Drug(s) Targeting Hemoglobin (HB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Voxelotor DMCS6M5 Sickle-cell disorder 3A51 Approved [6]
Iron Dextran DM5OY70 Iron-deficiency anemia 3A00 Approved [2]
PolyHeme DMV8EXG Blood forming organ disorder JB64.1 Phase 3 [7]
Efaproxyn DMX7BM4 Lung cancer 2C25.0 Phase 3 [8]
Hemoglobin raffimer DMMTL7V Anemia 3A00-3A9Z Phase 2/3 [9]
FBS-0701 DMR3952 Iron overload disease 5C64.10 Phase 2 [10]
HQK-1001 DM7QUN0 Beta thalassemia 3A50.2 Phase 2 [11]
5-hydroxymethyl-2-furfural DMPFVJB Anemia 3A00-3A9Z Phase 2 [12]
OXY-111A DMTH75R Cardiovascular disease BA00-BE2Z Phase 1/2 [13]
CTX110 DMJ7LP0 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hemoglobin (HB) TTQO71U HBA_HUMAN Activator [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Sodium/bile acid cotransporter 7 (SLC10A7) DTG1RJO NTCP7_HUMAN Substrate [3]
Natural resistance-associated macrophage protein 2 (SLC11A2) DTVKMHD NRAM2_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Friedreich ataxia protein (FXN) Main DME DEXVHDB FRDA_HUMAN Substrate [5]

References

1 Drug information of Iron, 2008. eduDrugs.
2 Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
3 Modulation of macrophage iron transport by Nramp1 (Slc11a1). Immunobiology. 2007;212(9-10):751-7.
4 Transmembrane topology of the mammalian Slc11a2 iron transporter. Biochemistry. 2009 Sep 8;48(35):8422-34.
5 Iron dysregulation in Friedreich ataxia. Semin Pediatr Neurol. 2006 Sep;13(3):166-75.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
7 Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
8 Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
9 Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
10 A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
11 A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
12 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
13 Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.
14 Clinical pipeline report, company report or official report of CRISPR Therapeutics.